Table 1.
Age-standardized incidence rate and incidence rate ratio of five major cancers and leukemia according to the Hebei Spirit oil spill exposure areas in Taean, Korea, 1999−2014.
| Cancer Type | Taean | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All | High Exposed Area | Low Exposed Area | ||||||||||
| Case 1 | SIR 2 | IRR1 3 (95% CI) | IRR2 4 (95% CI) | Case 1 | SIR 2 | IRR1 3 (95% CI) | IRR2 4 (95% CI) | Case 1 | SIR 2 | IRR1 3 (95% CI) | IRR2 4 (95% CI) | |
| Male | ||||||||||||
| All cancer (C00−C96) | ||||||||||||
| 1999−2003 | 753 | 318.0 | 1.1 (1.0, 1.2) | 1.0 (0.9, 1.1) | 284 | 309.7 | 1.1 (0.9, 1.2) | 1.0 (0.9, 1.1) | 420 | 288.8 | 1.0 (0.9, 1.1) | 0.9 (0.8, 1.0) |
| 2004−2008 | 872 | 314.6 | 1.0 (0.9, 1.1) | 0.9 (0.8, 1.0) | 323 | 309.2 | 1.0 (0.9, 1.1) | 0.9 (0.8, 1.0) | 547 | 315.2 | 1.0 (0.9, 1.1) | 0.9 (0.8, 1.0) |
| 2009−2014 | 1430 | 350.0 | 1.1 (1.0, 1.1) | 1.0 (0.9, 1.1) | 557 | 370.8 | 1.1 (1.0, 1.2) | 1.1 (1.0, 1.2) | 873 | 340.5 | 1.0 (1.0, 1.1) | 1.0 (0.9, 1.1) |
| All cancer (C00−C96) excluding thyroid (C73) | ||||||||||||
| 1999−2003 | 748 | 315.6 | 1.1 (1.0, 1.2) | 1.0 (0.9, 1.1) | 283 | 309.7 | 1.1 (0.9, 1.2) | 1.0 (0.9, 1.1) | 416 | 288.8 | 1.0 (0.9, 1.1) | 0.9 (0.8, 1.0) |
| 2004−2008 | 845 | 302.5 | 1.0 (0.9, 1.1) | 0.9 (0.8, 1.0) | 315 | 309.2 | 1.0 (0.9, 1.1) | 0.9 (0.8, 1.0) | 528 | 315.2 | 1.0 (0.9, 1.1) | 0.9 (0.8, 1.0) |
| 2009−2014 | 1369 | 325.3 | 1.1 (1.0, 1.1) | 1.0 (0.9, 1.1) | 531 | 370.8 | 1.1 (1.0, 1.2) | 1.0 (0.9, 1.1) | 838 | 340.5 | 1.0 (1.0, 1.1) | 1.0 (0.9, 1.1) |
| Stomach (C16) | ||||||||||||
| 1999−2003 | 207 | 89.6 | 1.3 (1.1, 1.6) | 1.2 (1.0, 1.4) | 69 | 81.4 | 1.2 (0.9, 1.6) | 1.1 (0.8, 1.4) | 123 | 85.2 | 1.3 (1.0, 1.5) | 1.1 (0.9, 1.4) |
| 2004−2008 | 183 | 63.9 | 1.0 (0.8, 1.1) | 0.9 (0.7, 1.0) | 69 | 60.2 | 0.9 (0.7, 1.2) | 0.8 (0.6, 1.1) | 114 | 64.1 | 1.0 (0.8, 1.2) | 0.9 (0.7, 1.1) |
| 2009−2014 | 277 | 67.1 | 1.1 (1.0, 1.3) | 1.1 (0.9, 1.2) | 101 | 64.4 | 1.1 (0.8, 1.3) | 1.0 (0.8, 1.3) | 176 | 67.5 | 1.1 (0.9, 1.3) | 1.1 (0.9, 1.3) |
| Lung (C33−C34) | ||||||||||||
| 1999−2003 | 128 | 51.2 | 1.0 (0.8, 1.2) | 0.9 (0.7, 1.0) | 58 | 55.1 | 1.1 (0.8, 1.4) | 0.9 (0.7, 1.2) | 60 | 40.3 | 0.8 (0.6, 1.0) | 0.7 (0.5, 0.9) |
| 2004−2008 | 173 | 58.0 | 1.2 (1.0, 1.4) | 1.0 (0.8, 1.2) | 58 | 53.3 | 1.1 (0.8, 1.5) | 0.9 (0.7, 1.2) | 115 | 62.8 | 1.3 (1.0, 1.6) | 1.1 (0.9, 1.3) |
| 2009−2014 | 257 | 53.2 | 1.2 (1.0, 1.3) | 1.0 (0.9, 1.2) | 102 | 56.3 | 1.2 (1.0, 1.6) | 1.1 (0.9, 1.4) | 155 | 53.1 | 1.2 (1.0, 1.4) | 1.0 (0.9, 1.2) |
| Colon (C18−C20) | ||||||||||||
| 1999−2003 | 55 | 22.7 | 0.7 (0.6, 0.9) | 0.9 (0.6, 1.1) | 22 | 21.3 | 0.7 (0.5, 1.0) | 0.8 (0.5, 1.2) | 32 | 21.7 | 0.7 (0.5, 0.9) | 0.8 (0.6, 1.2) |
| 2004−2008 | 102 | 37.8 | 0.9 (0.7, 1.0) | 1.1 (0.8, 1.3) | 37 | 34.8 | 0.8 (0.6, 1.1) | 1.0 (0.7, 1.4) | 65 | 38.2 | 0.9 (0.7, 1.1) | 1.1 (0.8, 1.4) |
| 2009−2014 | 197 | 48.7 | 1.0 (0.9, 1.2) | 1.0 (0.9, 1.3) | 69 | 50.2 | 1.0 (0.8, 1.4) | 1.1 (0.8, 1.5) | 128 | 49.0 | 1.0 (0.8, 1.2) | 1.1 (0.9, 1.3) |
| Liver (C22) | ||||||||||||
| 1999−2003 | 109 | 47.8 | 1.0 (0.9, 1.3) | 0.9 (0.7, 1.1) | 37 | 42.3 | 0.9 (0.7, 1.3) | 0.8 (0.6, 1.1) | 57 | 39.9 | 0.9 (0.7, 1.1) | 0.8 (0.6, 1.0) |
| 2004−2008 | 114 | 43.6 | 1.0 (0.9, 1.3) | 0.8 (0.7, 1.0) | 40 | 43.0 | 1.0 (0.7, 1.5) | 0.8 (0.6, 1.1) | 74 | 43.8 | 1.0 (0.8, 1.3) | 0.8 (0.7, 1.1) |
| 2009−2014 | 147 | 36.9 | 1.0 (0.9, 1.2) | 0.8 (0.7, 1.0) | 58 | 41.2 | 1.2 (0.8, 1.6) | 0.9 (0.7, 1.2) | 89 | 34.9 | 1.0 (0.8, 1.2) | 0.8 (0.6, 0.9) |
| Prostate (C61) | ||||||||||||
| 1999−2003 | 27 | 10.2 | 1.1 (0.7, 1.6) | 1.3 (0.8, 2.1) | 15 | 13.8 | 1.5 (0.8, 2.7) | 1.8 (0.9, 3.6) | 12 | 7.9 | 0.8 (0.5, 1.4) | 1.0 (0.5, 1.9) |
| 2004−2008 | 36 | 12.2 | 0.7 (0.5, 0.9) | 0.8 (0.6, 1.1) | 14 | 12.3 | 0.7 (0.4, 1.0) | 0.8 (0.5, 1.3) | 22 | 11.8 | 0.6 (0.5, 0.9) | 0.8 (0.5, 1.1) |
| 2009−2014 | 143 | 30.3 | 1.2 (1.0, 1.4) | 1.2 (1.0, 1.5) | 62 | 33.9 | 1.3 (1.0, 1.8) | 1.4 (1.0, 1.9) | 81 | 28.3 | 1.1 (0.9, 1.4) | 1.2 (0.9, 1.5) |
| Leukemia (C91−C95) | ||||||||||||
| 1999−2003 | 14 | 6.6 | 1.3 (0.7, 2.3) | 1.1 (0.6, 2.2) | 5 | 6.6 | 1.3 (0.4, 3.8) | 1.1 (0.4, 3.5) | 9 | 6.6 | 1.2 (0.6, 2.6) | 1.1 (0.5, 2.5) |
| 2004−2008 | 16 | 8.9 | 1.6 (0.8, 3.3) | 1.3 (0.6, 2.5) | 7 | 10.6 | 1.9 (0.5, 7.7) | 1.5 (0.4, 5.2) | 8 | 6.8 | 1.2 (0.6, 2.8) | 1.0 (0.4, 2.1) |
| 2009−2014 | 14 | 4.7 | 0.8 (0.4, 1.5) | 1.0 (0.5, 2.0) | 4 | 2.2 | 0.4 (0.2, 0.7) | 0.5 (0.2, 1.1) | 10 | 5.6 | 1.0 (0.5, 2.0) | 1.1 (0.5, 2.7) |
| Female | ||||||||||||
| All cancer (C00−C96) | ||||||||||||
| 1999−2003 | 474 | 192.8 | 1.0 (0.9, 1.2) | 1.1 (1.0, 1.3) | 159 | 169.1 | 0.9 (0.8, 1.1) | 1.0 (0.8, 1.2) | 288 | 184.8 | 1.0 (0.9, 1.2) | 1.1 (1.0, 1.3) |
| 2004−2008 | 679 | 264.4 | 1.1 (1.0, 1.2) | 1.1 (1.0, 1.3) | 233 | 251.2 | 1.1 (0.9, 1.3) | 1.1 (0.9, 1.3) | 446 | 266.9 | 1.1 (1.0, 1.2) | 1.2 (1.0, 1.3) |
| 2009−2014 | 905 | 325.6 | 1.0 (1.0, 1.1) | 1.1 (1.0, 1.2) | 358 | 295.6 | 1.0 (0.8, 1.1) | 1.0 (0.8, 1.2) | 738 | 327.0 | 1.1 (1.0, 1.2) | 1.1 (1.0, 1.2) |
| All cancer (C00−C96) excluding thyroid (C73) | ||||||||||||
| 1999−2003 | 434 | 170.0 | 1.0 (0.9, 1.2) | 1.2 (1.0, 1.3) | 148 | 155.7 | 0.9 (0.8, 1.2) | 1.1 (0.9, 1.3) | 259 | 162.0 | 1.0 (0.9, 1.1) | 1.1 (1.0, 1.3) |
| 2004−2008 | 527 | 185.4 | 1.0 (0.9, 1.1) | 1.1 (1.0, 1.2) | 188 | 184.6 | 1.0 (0.8, 1.2) | 1.1 (0.9, 1.3) | 338 | 186.7 | 1.0 (0.9, 1.1) | 1.1 (0.9, 1.3) |
| 2009−2014 | 805 | 198.3 | 1.0 (0.9, 1.1) | 1.1 (1.0, 1.2) | 270 | 188.2 | 0.9 (0.8, 1.2) | 1.0 (0.8, 1.3) | 535 | 204.8 | 1.0 (0.9, 1.1) | 1.1 (1.0, 1.3) |
| Thyroid (C73) | ||||||||||||
| 1999−2003 | 40 | 20.2 | 1.2 (0.8, 1.7) | 1.0 (0.7, 1.5) | 11 | 13.3 | 0.8 (0.4, 1.4) | 0.7 (0.4, 1.2) | 29 | 22.7 | 1.4 (0.9, 2.1) | 1.1 (0.7, 1.8) |
| 2004−2008 | 153 | 76.7 | 1.4 (1.1, 1.7) | 1.3 (1.1, 1.7) | 45 | 66.6 | 1.2 (0.8, 1.8) | 1.2 (0.8, 1.8) | 108 | 80.2 | 1.5 (1.1, 1.9) | 1.4 (1.1, 1.8) |
| 2009−2014 | 291 | 119.3 | 1.1 (1.0, 1.3) | 1.1 (0.9, 1.2) | 88 | 107.4 | 1.0 (0.8, 1.4) | 1.0 (0.7, 1.3) | 203 | 122.2 | 1.2 (1.0, 1.4) | 1.1 (0.9, 1.3) |
| Breast (C50) | ||||||||||||
| 1999−2003 | 57 | 31.9 | 1.1 (0.8, 1.5) | 1.8 (1.2, 2.6) | 17 | 28.1 | 1.0 (0.6, 1.7) | 1.5 (0.8, 3.1) | 40 | 33.4 | 1.2 (0.8, 1.7) | 1.8 (1.2, 2.9) |
| 2004−2008 | 75 | 39.3 | 1.0 (0.8, 1.3) | 1.4 (1.0, 1.9) | 25 | 42.1 | 1.1 (0.6, 1.9) | 1.4 (0.8, 2.8) | 50 | 38.7 | 1.0 (0.7, 1.3) | 1.3 (0.9, 1.9) |
| 2009−2014 | 118 | 46.4 | 0.9 (0.8, 1.1) | 1.4 (1.0, 1.8) | 35 | 39.5 | 0.8 (0.5, 1.2) | 1.2 (0.7, 1.9) | 83 | 47.6 | 1.0 (0.8, 1.2) | 1.4 (1.0, 1.9) |
| Colon (C18−C20) | ||||||||||||
| 1999−2003 | 60 | 20.9 | 1.1 (0.8, 1.5) | 1.3 (0.9, 1.9) | 16 | 11.8 | 0.6 (0.4, 1.0) | 0.7 (0.4, 1.2) | 42 | 24.5 | 1.3 (0.9, 1.9) | 1.5 (1.0, 2.3) |
| 2004−2008 | 66 | 21.0 | 0.9 (0.7, 1.1) | 0.9 (0.6, 1.2) | 22 | 19.9 | 0.8 (0.5, 1.4) | 0.8 (0.5, 1.4) | 44 | 21.8 | 0.9 (0.7, 1.2) | 0.9 (0.6, 1.3) |
| 2009−2014 | 130 | 23.0 | 0.9 (0.7, 1.0) | 0.9 (0.7, 1.2) | 39 | 17.9 | 0.7 (0.5, 0.9) | 0.7 (0.5, 1.0) | 91 | 25.7 | 1.0 (0.8, 1.2) | 1.0 (0.8, 1.4) |
| Stomach (C16) | ||||||||||||
| 1999−2003 | 82 | 29.1 | 1.1 (0.8, 1.4) | 1.1 (0.8, 1.4) | 28 | 29.4 | 1.1 (0.6, 1.8) | 1.1 (0.6, 1.9) | 49 | 27.3 | 1.0 (0.7, 1.3) | 1.0 (0.7, 1.4) |
| 2004−2008 | 96 | 31.3 | 1.2 (0.9, 1.5) | 1.1 (0.8, 1.5) | 32 | 25.3 | 0.9 (0.6, 1.6) | 0.9 (0.5, 1.5) | 64 | 34.0 | 1.3 (0.9, 1.7) | 1.2 (0.9, 1.7) |
| 2009−2014 | 139 | 31.6 | 1.2 (1.0, 1.6) | 1.1 (0.9, 1.5) | 46 | 26.8 | 1.1 (0.6, 1.7) | 1.0 (0.6, 1.6) | 93 | 33.4 | 1.3 (1.0, 1.8) | 1.2 (0.9, 1.6) |
| Lung (C33−C34) | ||||||||||||
| 1999−2003 | 46 | 14.5 | 1.2 (0.8, 1.6) | 1.1 (0.8, 1.7) | 19 | 11.8 | 0.9 (0.6, 1.5) | 0.9 (0.6, 1.5) | 22 | 12.7 | 1.0 (0.6, 1.6) | 1.0 (0.6, 1.6) |
| 2004−2008 | 60 | 15.4 | 1.1 (0.8, 1.5) | 1.4 (1.0, 2.1) | 18 | 11.9 | 0.9 (0.5, 1.4) | 1.1 (0.6, 2.0) | 42 | 18.0 | 1.3 (0.9, 1.9) | 1.7 (1.1, 2.6) |
| 2009−2014 | 90 | 15.3 | 1.0 (0.8, 1.3) | 1.2 (0.8, 1.6) | 37 | 19.8 | 1.3 (0.7, 2.6) | 1.5 (0.7, 3.1) | 53 | 14.3 | 1.0 (0.7, 1.3) | 1.1 (0.8, 1.5) |
| Leukemia (C91−C95) | ||||||||||||
| 1999−2003 | 11 | 5.1 | 1.3 (0.6, 2.8) | 1.5 (0.6, 3.7) | 2 | 1.4 | 0.4 (0.2, 0.8) | 0.4 (0.1, 1.2) | 7 | 5.0 | 1.3 (0.5, 3.2) | 1.5 (0.5, 4.2) |
| 2004−2008 | 13 | 5.7 | 1.4 (0.6, 3.1) | 1.1 (0.5, 2.5) | 6 | 10.8 | 2.7 (0.5, 15.2) | 2.1 (0.4, 10.3) | 7 | 3.9 | 1.0 (0.4, 2.2) | 0.8 (0.3, 1.9) |
| 2009−2014 | 13 | 7.3 | 1.8 (0.7, 4.5) | 1.9 (0.7, 5.0) | 6 | 20.8 | 5.1 (0.7, 36.3) | 5.3 (0.7, 39.1) | 7 | 4.2 | 1.0 (0.4, 2.8) | 1.1 (0.3, 3.3) |
1 The number of cases in Taean may vary in terms of the sum of the high-exposure and low-exposure areas, in situations in which address details were absent; 2 Standardized incidence rate: Rate per 100,000; The standard population was the Korean mid-year population in 2000; 3 The standardized incidence rate ratio was calculated as the standardized incidence rate in Taean divided by that in Korea and the 95% CI was estimated using the standardized incidence rate and the formula proposed by Boyle P. and Parkin D.M (“Statistical methods for registries” from book of “Cancer Registration: Principles and Methods” (IARC Scientific Publications No. 95)); 4 The standardized incidence rate ratio was calculated as the standardized incidence rate in Taean divided by that in the coastal area and the 95% CI was estimated using the standardized incidence rate and the above-stated formula. The coastal areas were selected based on their similarities to Taean, in terms of their characteristics and population size. This has been illustrated in Figure 1. CI, confidence interval; SIR, standardized incidence rate; IRR, incidence rate ratio.